Table 2.
Relationship between mechanisms of integration of HPV and clinical, biological and pathological characteristics of the 272 patients with HPV-positive cervical cancer.
| Number of patients (%) | |||||
|---|---|---|---|---|---|
| HPV insertiona | Patients (%) | EPI | 2J | MJ | p valueb |
| Total | 272 (100.0) | 33 (12.1) | 117 (43.0) | 122 (44.9) | |
| Age | |||||
| ≤50 | 140 (51.5) | 11 (33.3) | 60 (51.3) | 69 (56.6) | 0.061 (NS) |
| >50 | 132 (48.5) | 22 (66.7) | 57 (48.7) | 53 (43.4) | |
| Histologic subtype | |||||
| Squamous cell carcinoma | 230 (84.6) | 27 (81.8) | 92 (78.6) | 111 (91.1) | 0.14 (NS) |
| Adenocarcinoma | 27 (9.9) | 3 (9.1) | 18 (15.4) | 6 (4.9) | |
| Adenosquamous carcinoma | 10 (3.7) | 2 (6.1) | 4 (3.4) | 4 (3.3) | |
| Mixed form or undifferenciated | 5 (1.8) | 1 (3.0) | 3 (2.6) | 1 (0.8) | |
| HPV status | |||||
| Genotype 16 | 155 (57.0) | 25 (75.8) | 44 (37.6) | 86 (70.5) | <0.0001 |
| Genotype 18 | 36 (13.2) | 0 (0.0) | 24 (20.5) | 12 (9.8) | |
| Genotype 45 | 27 (9.9) | 0 (0.0) | 24 (20.5) | 3 (2.5) | |
| Genotype 31 | 9 (3.3) | 2 (6.1) | 4 (3.4) | 3 (2.5) | |
| Genotype 33 | 11 (4.0) | 3 (9.1) | 4 (3.4) | 4 (3.3) | |
| Other genotypesc | 34 (12.5) | 3 (9.1) | 17 (14.5) | 14 (11.5) | |
| Stage FIGO | |||||
| I/II | 205 (75.4) | 25 (75.8) | 86 (73.5) | 94 (77.0) | 0.82 (NS) |
| III/IV | 67 (24.6) | 8 (24.2) | 31 (26.5) | 28 (23.0) | |
| Lymph node | |||||
| Yes | 167 (61.4) | 19 (57.6) | 81 (69.2) | 67 (54.9) | 0.067 (NS) |
| No | 105 (38.6) | 14 (42.4) | 36 (30.8) | 55 (45.1) | |
| Pelvis lymph node | |||||
| Yes | 165 (60.7) | 19 (57.6) | 80 (68.4) | 66 (54.1) | 0.072 (NS) |
| No | 107 (39.3) | 14 (42.4) | 37 (31.6) | 56 (45.9) | |
| Para-aortic lymph node | |||||
| Yes | 43 (15.8) | 3 (9.1) | 20 (17.1) | 20 (16.4) | 0.52 (NS) |
| No | 229 (84.2) | 30 (90.9) | 97 (82.9) | 102 (83.6) | |
| Initial therapy | |||||
| Surgery | 54 (19.9) | 7 (21.2) | 21 (17.9) | 26 (21.3) | 0.86 (NS) |
| Radiotherapy | 176 (64.7) | 22 (66.7) | 75 (64.1) | 79 (64.8) | |
| Neoadjuvant chemotherapy | 42 (15.4) | 4 (12.1) | 21 (17.9) | 17 (13.9) | |
| PIK3CA mutational statusd | |||||
| WT | 182 (67.7) | 15 (46.9) | 84 (72.4) | 83 (68.6) | 0.023 |
| Mutated | 87 (32.3) | 17 (53.1) | 32 (27.6) | 38 (31.4) | |
Significant results are displayed in bold.
NS not significant.
aHPV insertion: EPI episomal, 2J 2 junctions, MJ multiple junctions.
bChi-square test; p values for comparison of the EPI group vs. the 2J group vs. the MJ group for each parameter.
cOther HPV genotypes: 39, 42, 52, 56, 58, 59, 68, 70, 73, and 82.
dInformation available for 269 patients.